⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

August 1, 2015Advances in TherapyOpen Access

The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Mundipharma International Ltd.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Jha et al. (2015) studied this question.

synapsesocial.com/papers/69dac69f387cf70698687af0 https://doi.org/10.1007/s12325-015-0233-1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD).Cohort Study · 1996 · 1,033 citations
2Biologic systemic therapy for moderate-to-severe psoriasis: A reviewRCT · 2013 · 10 citations
3A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasisCohort Study · 2010 · 69 citations
4The role of TNF inhibitors in psoriasis therapy: new implications for associated comorbiditiesReview · 2009 · 78 citations
5Infliximab for the treatment of rheumatoid arthritisRCT · 2002 · 128 citations